REVIEW

Defining the functional states of Th17 cells [v1; ref status: indexed, http://f1000r.es/51y]

Youjin Lee¹, Vijay Kuchroo¹,²

¹Evergrande Center for Immunologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, MA, 02115, USA
²Genomic and Biotechnology Section, Faculty of Science, King Abdulaziz University, Jeddah, 21589, Saudi Arabia

Abstract

The molecular mechanisms governing T helper (Th) cell differentiation and function have revealed a complex network of transcriptional and protein regulators. Cytokines not only initiate the differentiation of CD4 Th cells into subsets but also influence the identity, plasticity and effector function of a T cell. Of the subsets, Th17 cells, named for producing interleukin 17 (IL-17) as their signature cytokine, secrete a cohort of other cytokines, including IL-22, IL-21, IL-10, IL-9, IFNγ, and GM-CSF. In recent years, Th17 cells have emerged as key players in host defense against both extracellular pathogens and fungal infections, but they have also been implicated as one of the main drivers in the pathogenesis of autoimmunity, likely mediated in part by the cytokines that they produce. Advances in high throughput genomic sequencing have revealed unexpected heterogeneity in Th17 cells and, as a consequence, may have tremendous impact on our understanding of their functional diversity. The assortment in gene expression may also identify different functional states of Th17 cells. This review aims to understand the interplay between the cytokine regulators that drive Th17 cell differentiation and functional states in Th17 cells.

This article is included in the F1000 Faculty Reviews channel.
T helper subsets and links to autoimmune inflammation

CD4 T cells are essential architects of host immune defense against pathogens\(^1\). Collectively, their effector function is mediated in part by a compilation of cytokines that directs differentiation, migration, homeostasis, regulation, and inflammation. Initially, CD4 T helper (Th) cells were grouped into two distinct subsets defined by production of unique cytokines: type 1 helper T cells (Th1) produce IFN\(\gamma\) as their signature cytokine and mediate immune responses against intracellular pathogens, and type 2 helper T cells (Th2) secrete interleukin (IL)-4, IL-5 and IL-13 and drive immune responses against extracellular pathogens, like parasites\(^3\). In recent years, the number of unique subsets has grown to include IL-9-producing Th9, follicular T helper cells (Tfh) and IL-17-producing Th17, as well as three subsets of T cells that regulate immune responses, including Type 1 regulatory cells (Tr1), follicular T regulatory cells (TfR) and T regulatory cell (Tregs) (Figure 1)\(^4\)–\(^6\). Each of the effector subsets is not only critical for orchestrating a proper immune response against specific pathogens but is also a major contributor in the pathogenesis of a number of autoimmune inflammatory diseases\(^7\).

For a number of years, IL-12-induced Th1 cells were thought to be the main drivers of autoimmunity, based on the findings that IFN\(\gamma\)-secreting CD4 T cells were frequently found at the site of inflammation and treatment with IFN\(\gamma\) led to exacerbated disease in multiple sclerosis patients\(^8\),\(^9\). IL-12 is a heterodimeric cytokine composed of two subunits, IL-12p35 and IL-12p40, and is a critical factor for the differentiation of Th1 cells\(^10\),\(^11\). CD4 T cells express a heterodimeric IL-12 receptor (IL-12R) composed of IL-12R\(\beta1\) and IL-12R\(\beta2\) subunits\(^12\),\(^17\). Upon exposure to IL-12, the master transcription factor Tbx21 is induced, which transactivates IFN-\(\gamma\), and the cells differentiate into Th1 cells\(^14\),\(^15\). The importance of Th1 cells in autoimmune diseases was further supported by findings that protection from experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis, was observed upon neutralization with anti-IL-12p40 or in IL-12p40\(^-/-\) mice\(^6\),\(^7\). However, it became clear that Th1 cells may not be the exclusive drivers for autoimmunity when it was discovered that mice lacking critical components of the Th1 differentiation pathway, such as IFN\(\gamma\), IFN\(\gamma\)R, IL-12R\(\beta2\), and IL-12p35, were highly susceptible to EAE, suggesting that Th1 cells may even be protective in autoimmune diseases\(^8\)–\(^22\).

**Discovery of IL-23- and Th17-associated pathogenic inflammation**

In the late 1990s, a novel cytokine called IL-23 that belongs to the IL-12 family of cytokines was discovered\(^23\). Interestingly, similar to the functional IL-12 cytokine, IL-23 had an IL-23 p19 subunit, which combined with the IL-12 p40 subunit of IL-12, to develop a functional heterodimeric cytokine\(^24\). Loss of either IL-23 p19 or IL-12 p40 chains made mice highly resistant to the development of EAE and other autoimmune diseases, suggesting that IL-23 is a cytokine critical for development of autoimmunity\(^17\),\(^25\),\(^26\). However, unlike IL-12, IL-23 did not induce IFN\(\gamma\) production from naïve CD4 T cells\(^24\),\(^27\), but it was suggested that IL-23 may be critical for the generation of IL-17-producing Th17 cells. A series of in vitro studies showed that IL-23 could not induce differentiation of naïve T cells into IL-17-producing Th17 cells. In fact, it was discovered

---

**Figure 1.** The diversity of CD4 subsets. CD4 T helper subsets identified with differentiating conditions as well as the signature cytokines they are known to produce. Th17 cells are further subtyped based on cytokine conditions that define pathogenic versus non-pathogenic states.
that the receptor for IL-23 was not even expressed on naïve CD4 T cells, suggesting that other cytokines besides IL-23 may be critical for the generation of Th17 cells. In fact, we and others showed that Th17 cells are differentiated in the presence of TGF-β1 and IL-6, which resulted in the induction of a unique master transcription factor called RORγt. While IL-23 was not required for the differentiation of Th17 cells, it was revealed to be a critical factor for stabilization of the Th17 phenotype and in evoking pathogenic properties in Th17 cells. With ensuing studies it became clear that IL-23, not IL-12, was the critical cytokine for driving autoimmune inflammation. IL-23p19−/−, IL-12p40−/− and IL-23R−/− mice were completely protected from developing a number of murine models of autoimmune diseases including EAE, psoriasis, and colitis. Consistently, Genome Wide Association Scans have reported a strong genetic linkage to single nucleotide polymorphisms (SNP) in IL-23 or IL-23R, with increased susceptibility to several human autoimmune diseases. However, the clearest role of Th17 cells in human autoimmune diseases was supported by clinical studies where neutralization of IL-17 by an anti-IL-17 antibody (Secukinumab) resulted in clinically beneficial results in a number of human autoimmune diseases, including psoriasis, ankylosing spondylitis, and multiple sclerosis.

**Heterogeneity within the Th17 subset**

Although Th17 cells have become synonymous with autoimmune tissue inflammation, it is now clear that not all Th17 cells are pathogenic or induce tissue inflammation. In human inflammatory bowel diseases (IBDs), neutralization of IL-17 or blockade of IL-17 receptor (IL-17Ra) resulted in disease exacerbation, suggesting a possible protective role by Th17 cells. IL-17-producing T cells that line the gut mucosa do not induce inflammation but have been shown to be necessary to maintain the barrier function of the gut. Commensal bacteria in the gut may play a critical role in the generation of Th17 cells in the lamina propria and, indeed, there is an absence of IL-17-producing cells in the lamina propria of the small intestines in germ-free mice. There is also evidence suggesting that IL-17 is required to prevent pathologic gut inflammation in a CD4 T cell-mediated transfer model of colitis, as cells lacking the capacity to produce IL-17, or the lack of IL-17R in recipient mice, resulted in exacerbated colitis. In addition, non-pathogenic Th17 cells, which do not produce IL-10, but instead produce IFNγ, have specificity for pathogens.

**Transcriptional gene signatures for pathogenic Th17 cells**

When we compared the gene expression profiles of all known possible in vitro differentiation combinations that induce pathogenic and non-pathogenic Th17 cells, we found 434 genes that were differentially expressed between these different Th17 subtypes. Of the 434 genes, 233 genes were differentially expressed between highly pathogenic and non-pathogenic Th17 cells. Based on the biological function, we identified a representative subset of 23 genes that was highly suggestive of driving pathogenicity. Pathogenic Th17 cells induced expression of various effector molecules that have been shown to be pro-inflammatory, such as Cxcl3, Ccl4, Ccl5, Csf2 (GM-CSF), Il13 (associated with Csf2), Il12, Gzmb (Granzyme B) and, interestingly, transcription factors that are associated with the Th1 phenotype such as Tbx21 (Tbet) and Stat4. Conversely, non-pathogenic Th17 cells revealed a gene signature that included molecules associated with regulation, such as Il10 and transcription factors that regulate IL-10 production, such as Ahr and Maf. Pathogenic Th17 cells in vitro differentiation of Th17 cells in order to develop a novel gene signature that functionally distinguishes Th17 subsets.

The dichotomous nature of Th17 cells may not be a mere in vitro cytokine artifact but may have occurred naturally as a consequence of evolutionary pressures to defend against different types of pathogens. Federica Sallusto’s group was first to show that human Th17 cells producing IL-10 in conjunction with IL-17 have specificity for *Staphylococcus aureus* infection. Conversely, Th17 cells that do not produce IL-10, but instead produce IFNγ with IL-17, have specificity for *Candida albicans* infection, suggesting that, evolutionarily, Th17 cells may have diverged to acquire different cytokine profiles, to become more adept in defense against specific pathogens. This is in line with clinical observations with immune-deficient patients, where the loss of transcription factor Stat3, which inhibits development of all Th17 cells, results in hyper IgE syndrome and the patients develop rampant *C. albicans* and *S. aureus* infections. Thus, based on our study, we’ve uncovered an interesting overlap in the gene expression profiles of Th17 cells specific for *C. albicans* or *S. aureus* in humans with pathogenic versus non-pathogenic Th17 cells in mice. The gene expression profile revealing an IL-17/IFNγ signature which was specific for *C. albicans* in humans had similarities to more pathogenic pro-inflammatory
murine Th17 cells which cause severe EAE. Conversely, the gene profile for IL-17/IL-10-producing Th17 cells specific for S. aureus were comparable to a more non-pathogenic, regulatory gene signature. This was highly suggestive of how evolutionary pressures have fine-tuned different effector cells for clearing different types of pathogens and utilized the same cells for the induction of tissue inflammation or to mediate tissue protection, albeit with small changes in the transcriptome.

Challenges in understanding the functional outcome of Th17 heterogeneity

It has become clear in recent years that Th17 cells may have divergent functions. We are just beginning to understand the functional consequences of this extensive heterogeneity of Th17 cells. Though gene expression profiling has endowed us with the ability to identify a signature that distinguishes pathogenic from non-pathogenic Th17 cells, we do not know how these cells are naturally derived in vivo or what their function is in mediating tissue homeostasis, effector function, inflammation or cancer. For example, do these pathogenic or non-pathogenic Th17 cells develop simultaneously during differentiation in the lymphoid tissue or is there plasticity in the development of Th17 cells such that they can inter-convert based on the environmental cues they receive? Or perhaps there is a sequential development: do non-pathogenic Th17 cells convert into pathogenic Th17 cells during the course of maturation or differentiation? Also, given that the location of the IL-17 producing cells in the peripheral tissue is critical in dictating their function, this raises the issue of how much the peripheral tissue microenvironment alters the developmental programming of Th17 cells. Much remains to be understood in terms of how and why Th17 cells retain heterogeneity and how it influences their functional states.

In recent years, examination of heterogeneity at a single-cell resolution has become possible by high throughput single-cell RNA sequencing of whole genomes and transcriptomes. Single-cell RNA sequencing allows for profiling and characterization of expression variability on a genomic scale, which provides us with the ability to correlate this genomic heterogeneity with functional differences in Th17 cells. In fact, single-cell RNA sequencing of Th17 cells obtained from different tissues and lymphoid organs is allowing identification of novel regulators of functional states (pathogenic versus non-pathogenic) of Th17 cells (unpublished observation from our lab). Transcriptomic analysis of T cells in the secondary lymphoid organs following activation does provide valuable clues into the differentiation state acquired by the T cells, but it does not identify the functional state that may be attained by Th17 cells upon arrival into the tissue niche. The functional states (pathogenic/non-pathogenic) of the Th17 cells may be partly dependent on the cytokine milieu and tissue microenvironment to which the cells migrate in order to mediate effector functions. Utilizing the pathogenicity gene signature derived from our earlier studies as one of the definable parameters used to analyze single-cell sequence data, our lab has discovered that the functional states of Th17 cells may be in constant flux as the T cells mediate tissue inflammation (unpublished observation). Uncovering key regulators that control effector functions of Th17 cells may permit novel treatment approaches for therapeutically inhibiting inflammation without affecting the protective functions of Th17 cells.

However, assigning function to these novel regulators will require genetic manipulation undertaken at a large scale. Unfortunately, the only way to confirm the function of a gene is through the use of knockout mice or genetic knockdowns in the cells and disease models. The use of viral vectors or transfection-based si-RNA delivery was not effective in this endeavor, due to the changes in either the differentiation or cell viability induced by these manipulations. Also, to generate a knockout mouse of every novel regulator identified at a single-cell level is an impossible undertaking. To bypass these obvious limitations, our lab in collaboration with Hongkun Park’s lab has developed a novel system of silicon nanowire perturbations where newly discovered candidate genes can be knocked-down at a large scale, which has improved the process of functional validation. Silicon nanowire perturbation allows for the delivery of siRNA effectively and efficiently into native T cells without the burden of activation or differentiation.

The future

Armed with next-generation sequencing and silicon nanowire knockdowns, the pathogenic potential of subpopulations within Th17 cells can be revealed and novel regulators that may drive functional heterogeneity can be effectively established. Understanding the epigenetic and transcriptional controls of various functional states of Th17 cells will undoubtedly reveal new treatment paradigms for autoimmune diseases as well as give us deeper insight into the complex network that drives inflammatory versus tissue-protective functions of Th17 cells.

Grant information

The author(s) declared that no grants were involved in supporting this work.
Ann Rev Immunol. 2010; 28: 445–489.

7. Cox CA, Shi G, Yin H, et al.: Both Th1 and Th17 are immunopathogenic but differ in other key biological activities. J Immunol. 2008; 180(11): 7141–22.

8. Zamul SS, Steeves L: The T lymphocyte in experimental allergic encephalomyelitis. Ann Rev Immunol. 1990; 8: 579–621.

9. Panitch HS, Hirsch R, Haley AS, et al.: Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet. 1987; 1(8638): 893–895.

10. Wolf SF, Temple PA, Kobayashi M, et al.: Cloning of CDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells. J Immunol. 1991; 146(6): 3074–3081.

11. Stern AS, Magram J, Presky DH: Interleukin-12 as an integral cytokine in the immune response. Life Sci. 1996; 58(8): 639–654.

12. Chua AO, Chizzonite R, Desai BB, et al.: Novel transcription factor, T-bet, directs Th1 lineage commitment. Cell. 2000; 100(6): 655–663.

13. Brok Herbert PM, van Meurs M, Blezer E, et al.: Prevention of experimental autoimmune encephalomyelitis in common marmosets using an anti-IL-12 monoclonal antibody. J Immunol. 2002; 169(11): 6564–6566.

14. Langrish CL, Chen Y, Blumenschein WM, et al.: IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med. 2005; 202(1): 233–240.

15. Gran B, Zhang G, Yu S, et al.: IL-12p35-deficient mice are susceptible to experimental autoimmune encephalomyelitis: evidence for redundancy in the IL-12 system in the induction of central nervous system autoimmune demyelination. J Immunol. 2002; 169(12): 7104–7110.

16. Veldhoen M, Hocking RU, Akins CJ, et al.: TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity. 2006; 24(2): 179–189.

17. Cargill M, Schrodi SJ, Chang M, et al.: A large-scale genetic association study identifies IL-12B as a susceptibility gene for Graves' disease. Nature. 2006; 441(7090): 235–238.

18. Mangan PR, Harrington LE, Quinn DB, et al.: Transforming growth factor-beta induces development of the Th17 lineage. Nature. 2004; 441(7090): 231–234.

19. Cua DJ, Sherlock J, Chen Y, et al.: IL-23: one cytokine in control of autoimmunity. Annu Rev Immunol. 2006; 24: 3223–3227.

20. Maze CA, Langrish CL, Chen Y, et al.: Divergent pro-and anti-inflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med. 2003; 198(12): 1951–7.

21. Núñez C, Dema B, Cénit MC, et al.: IL23R and IL23A roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med. 2003; 200(9): 1167–72.

22. Blotwijk CA, Langrish CL, Chen Y, et al.: Interleukin-23-mediated IL-17 production is critical for the development of experimental autoimmune encephalomyelitis. J Exp Med. 2002; 196(5): 595–607.

23. Becher B, Durell BG, Noelle RJ, et al.: IL-23 promotes a distinct CD4 effector category. Immunity. 2004; 20(2): 715–725.

24. Li G, Lu K, Shi J, et al.: Genetic variation at IL23R and IL23A is a major susceptibility gene for Graves' ophthalmopathy: the IL-23/T-helper 17 axis extends to thyroid autoimmunity. J Clin Endocrinol Metab. 2008; 93(3): 1077–1081.

25. Cui DJ, Sherlock J, Chen Y, et al.: Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature. 2003; 421(6924): 744–748.

26. Croxford AL, Mair F, Becher B: IL-23: one cytokine in control of autoimmunity. Eur J Immunol. 2012; 42(9): 2263–2273.
dependent on IL-1- and IL-23-induced production of the cytokine GM-CSF. Nat Immunol. 2011;12(6): 568–575.

62. Chung Y, Chang SH, Martinez GJ, et al.: Critical regulation of early Th17 cell differentiation by interleukin-1 signaling. Immunity; 2009; 30(4): 576–587.

63. Zielinski CE, Mele F, Aochenbremer D, et al.: Pathogen-induced human T\(_\text{H}17\) cells produce IFN-\(\gamma\) or IL-10 and are regulated by IL-17. Nature. 2012; 484(7395): 514–518.

64. Ma CS, Chew GY, Simpson N, et al.: Deficiency of Th17 cells in hyper IgE syndrome due to mutations in STAT3. J Exp Med. 2008; 205(7): 1551–1557.

65. Yosef N, Shalek AK, Gaulinomme JT, et al.: Dynamic regulatory network controlling T\(_{H}17\) cell differentiation. Nature. 2013; 496(7446): 461–468.

66. Kalisky T, Blainey P, Quake SR: Genomic analysis at the single-cell level. Annu Rev Genet. 2011; 45: 431–445.

67. Blainey PC, Quake SR: Dissecting genomic diversity, one cell at a time. Nat Methods. 2014; 11(1): 19–21.

68. Trombetta JJ, Gennert D, Lu D, et al.: Preparation of Single-Cell RNA-Seq Libraries for Next Generation Sequencing. Curr Protoc Mol Biol. 2014; 107: 4.22.1–4.22.17.

69. Shalek AK, Satija R, Adiconis X, et al.: Single-cell transcriptomics reveals bimodality in expression and splicing in immune cells. Nature. 2013; 498(7453): 236–240.

70. Yosef N, Zalevsky S, Rubinstein AD, et al.: ANAT: a tool for constructing and analyzing functional protein networks. Sci Signal. 2011; 4(195): p11.

71. Dandalian V, Herpes B, Noraz N, et al.: Lentivirus-mediated gene transfer in primary T cells is enhanced by a central DNA flap. Gene Ther. 2001; 8(3): 190–198.

72. McManus MT, Haines BB, Dillon CP, et al.: Small interfering RNA-mediated gene silencing in T lymphocytes. J Immunol. 2002; 169(10): 5754–5760.

73. Shalek AK, Robinson JT, Karp ES, et al.: Vertical silicon nanowires as a universal platform for delivering biomolecules into living cells. Proc Natl Acad Sci U S A. 2010; 107(5): 1870–1875.

74. Shalek AK, Gaulinomme JT, Wang L, et al.: Nanowire-mediated delivery enables functional interrogation of primary immune cells: application to the analysis of chronic lymphocytic leukemia. Nano lett. 2012; 12(12): 6498–6504.
Open Peer Review

Current Referee Status: ✔️ ✔️ ✔️

Version 1

Referee Report 28 May 2015
doi:10.5256/f1000research.6550.r8801

Dan R. Littman  
New York University School of Medicine, New York, USA

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Competing Interests: No competing interests were disclosed.

Referee Report 28 May 2015
doi:10.5256/f1000research.6550.r8800

Jagadeesh Bayry  
French National Institute of Health and Research, Paris, France

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Competing Interests: No competing interests were disclosed.

Referee Report 28 May 2015
doi:10.5256/f1000research.6550.r8799

Richard A. Flavell, Nicola Gagliani  
Yale School of Medicine, Connecticut, USA

We have read this submission. We believe that we have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Competing Interests: No competing interests were disclosed.